India to Taiwan: Acyclovir Export Trade Route

To import Acyclovir formulations into Taiwan, the following approvals and registrations are necessary:

1. Drug License Application: All pharmaceutical products intended for import must obtain a drug license issued by the TFDA. This involves submitting a comprehensive dossier that includes product details, manufacturing processes, and quality control measures.

2. Dossier Format: The TFDA accepts dossiers in the Common Technical Document (CTD) format, which encompasses modules on administrative information, quality, safety, and efficacy.

3. Approval Timelines: While specific timelines can vary, the TFDA typically processes drug license applications within a few months, depending on the completeness and complexity of the submission.

4. Product Registration Fees: Applicants are required to pay registration fees as stipulated by the TFDA. The exact fees depend on the type of application and are subject to periodic updates.

5. GMP Inspection Requirements: Indian manufacturing facilities producing Acyclovir formulations must comply with Good Manufacturing Practice (GMP) standards recognized by the TFDA. This includes submitting a Plant Master File (PMF) and may involve on-site inspections to verify compliance.

Indian exporters of Acyclovir formulations must meet the following GMP standards to supply products to Taiwan:

1. GMP Certification: Manufacturers must possess GMP certificates issued by competent health authorities in their country, such as the Central Drugs Standard Control Organization (CDSCO) in India. These certificates should confirm compliance with standards equivalent to the PIC/S GMP guidelines.

2. Approved Facilities: The TFDA maintains a list of foreign pharmaceutical manufacturers approved for importation. Indian facilities seeking approval must submit detailed documentation, including GMP certificates and Site Master Files, for evaluation.

3. Inspections and Regulatory Actions: The TFDA conducts periodic inspections and reviews of foreign manufacturing facilities. Any non-compliance identified during these inspections can lead to regulatory actions, including suspension or revocation of import licenses.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Taiwan:

1. Alignment with International Standards: In September 2025, the TFDA announced the synchronization of domestic GMP regulations with international practices, enhancing the quality standards for imported pharmaceuticals.

2. Enhanced Oversight: In November 2025, the TFDA increased scrutiny of online pharmaceutical sales to safeguard consumer rights, indirectly affecting importers by ensuring stricter compliance with regulatory standards.

3. Regulatory Updates: Throughout 2024 and 2025, the TFDA issued several updates to its guidelines, emphasizing the importance of GMP compliance and the need for foreign manufacturers to adhere to Taiwan's regulatory requirements.

These developments underscore the TFDA's commitment to ensuring the safety and efficacy of pharmaceutical products available in Taiwan, necessitating strict compliance from foreign exporters.

Acyclovir is a widely used antiviral medication in Taiwan, primarily prescribed for the treatment of herpes simplex virus infections, including genital herpes and cold sores, as well as for the management of varicella-zoster virus infections like chickenpox and shingles. The demand for Acyclovir formulations is influenced by several factors:

• Disease Prevalence: The incidence of herpes simplex and varicella-zoster infections remains consistent, contributing to steady demand for antiviral treatments.

• Healthcare Spending: Taiwan's healthcare expenditure has been on an upward trajectory, with a focus on enhancing pharmaceutical accessibility and affordability.

• Aging Population: An increasing elderly demographic is more susceptible to varicella-zoster virus reactivation, leading to higher occurrences of shingles, thereby boosting the need for Acyclovir formulations.

• Universal Health Coverage: Taiwan's National Health Insurance (NHI) program ensures that a significant portion of the population has access to essential medications, including antivirals like Acyclovir.

While specific market size data for Acyclovir in Taiwan for 2024-2025 is not readily available, the combination of these factors suggests a stable and potentially growing market for Acyclovir formulations. Taiwan's pharmaceutical industry is robust, with both domestic manufacturing capabilities and reliance on imports to meet demand. The exact proportion of domestically produced versus imported Acyclovir formulations is not specified, but imports play a crucial role in supplementing local production to ensure adequate supply.

Pharmaceutical products classified under HS code 30049099, including Acyclovir formulations, are subject to the following import regulations in Taiwan:

• Import Duty: 0% (MFN rate)

• Value-Added Tax (VAT): 5%

• Other Charges: Standard customs processing fees may apply, but no additional specific charges are imposed on pharmaceutical imports under this classification.

Taiwan does not have a Free Trade Agreement (FTA) with India that affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on Acyclovir formulations imported from India. The 0% import duty rate under the MFN status facilitates the importation of pharmaceutical products, ensuring that Taiwanese consumers have access to a diverse range of medications.

India is a significant supplier of Acyclovir formulations to Taiwan, accounting for $3.0 million USD in trade value, representing 2.4% of India's total Acyclovir formulation exports. The primary Indian exporter is MYLAN LABORATORIES LIMITED, contributing $2.9 million USD to this trade route.

Other major countries supplying Acyclovir formulations to Taiwan include the United States and European Union member states. While specific import values from these countries are not detailed, they are known to be key players in the global pharmaceutical market.

India's share of Taiwan's total Acyclovir imports is substantial, indicating a strong trade relationship in this sector. Indian pharmaceutical manufacturers are recognized for their cost-effective production capabilities, often offering competitive pricing compared to counterparts in the United States and the European Union. This pricing advantage, coupled with adherence to international quality standards, positions Indian exporters favorably in the Taiwanese market.

In summary, Taiwan's Acyclovir market is characterized by steady demand driven by disease prevalence, healthcare investment, and demographic trends. The import tariff structure, with a 0% duty rate, supports the influx of pharmaceutical products, including those from India. India's competitive pricing and quality manufacturing have solidified its role as a key supplier of Acyclovir formulations to Taiwan, alongside contributions from the United States and European Union manufacturers.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. The country has established a robust manufacturing infrastructure, with over 752 FDA-approved facilities and 2,050 WHO-GMP-certified plants as of 2024. This extensive network enables large-scale production of finished dosage forms, including tablets, capsules, syrups, and injections. The cost-effectiveness of Indian pharmaceutical manufacturing is attributed to economies of scale, a skilled workforce, and favorable regulatory policies. These factors collectively position India as a preferred source for Acyclovir formulations globally.

India's Acyclovir formulation exports are competitively priced compared to those from China and the European Union. The cost advantage is primarily due to India's efficient manufacturing processes and lower labor costs. In terms of quality, Indian pharmaceutical products meet stringent international standards, with a significant number of manufacturing facilities approved by regulatory bodies such as the FDA and WHO. Taiwan's regulatory authorities recognize these certifications, facilitating smoother market entry for Indian formulations. The supply reliability of Indian manufacturers is well-established, with a consistent track record of fulfilling international orders without significant disruptions.

The India-Taiwan supply chain for Acyclovir formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging facilities. Indian manufacturers have demonstrated compliance with international regulatory standards, ensuring product quality and safety. As of 2024, there have been no significant supply disruptions reported in this trade route. Leading Indian pharmaceutical companies continue to invest in expanding their production capacities to meet growing global demand, further enhancing supply reliability.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply chain disruptions and ensure a steady supply of Acyclovir formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): Understand and negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Establish Clear Payment Terms: Familiarize yourself with common payment practices in India-Taiwan pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to build trust and ensure smooth transactions.

• Conduct Thorough Supplier Qualification: Perform comprehensive due diligence, including audits of manufacturing facilities, to verify compliance with international quality standards and regulatory requirements.

• Monitor Regulatory Compliance: Stay updated on both Indian and Taiwanese regulatory changes to ensure continuous compliance and avoid potential trade barriers.

Before engaging with an Indian supplier for Acyclovir formulations, Taiwan buyers should adhere to the following pre-qualification steps:

1. Verify Supplier's Registration with CDSCO: Confirm that the Indian manufacturer is registered with the Central Drugs Standard Control Organization (CDSCO) and possesses a valid manufacturing license. This ensures compliance with Indian regulatory standards.

2. Assess GMP Certification: Obtain the supplier's Good Manufacturing Practice (GMP) certificate to ensure adherence to quality manufacturing standards.

3. Review Drug Master File (DMF): Request the supplier's DMF for Acyclovir formulations to evaluate detailed information on the manufacturing process, controls, and stability data.

4. Confirm Product Registration with Taiwan FDA: Ensure that the Acyclovir formulations are registered with the Taiwan Food and Drug Administration (TFDA) and have the necessary market authorization.

5. Evaluate Quality Management Systems: Assess the supplier's quality management systems, including standard operating procedures, quality control measures, and compliance with international standards.

6. Check for International Certifications: Verify if the supplier holds certifications such as WHO-GMP, PIC/S compliance, or approvals from stringent regulatory authorities (SRAs) like the US FDA or EMA.

7. Review Export History: Analyze the supplier's export history to ensure a consistent track record of supplying Acyclovir formulations to international markets.

8. Conduct Risk Assessment: Perform a risk assessment considering factors like geopolitical stability, supply chain reliability, and potential regulatory changes affecting the supplier.

When sourcing Acyclovir formulations from Indian manufacturers, Taiwan buyers should request the following documents:

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified quality standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory compliance.

3. Good Manufacturing Practice (GMP) Certificate: Demonstrates that the manufacturing facility complies with GMP standards, ensuring product quality and safety.

4. Stability Data: Includes stability studies conducted under International Council for Harmonisation (ICH) guidelines, providing information on the product's shelf life and storage conditions.

5. Batch Manufacturing Records: Detailed records of the manufacturing process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and other pertinent information about the drug product.

7. Free Sale Certificate: Issued by CDSCO, indicating that the product is approved for sale in India and is freely marketed without restrictions.

8. Insurance Certificates: Proof of product liability insurance, ensuring coverage in case of product-related issues.

When evaluating Indian suppliers for Acyclovir formulations, be vigilant for the following warning signs:

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies such as the US FDA or WHO-GMP suspensions indicate compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about product shelf life and efficacy.

4. Limited Export Experience: No history of exporting to regulated markets may indicate a lack of experience in meeting stringent international standards.

5. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential compliance or quality issues.

6. Inconsistent Documentation: Discrepancies or incomplete information in provided documents can indicate poor record-keeping or attempts to conceal deficiencies.

To ensure the quality and compliance of Acyclovir formulations from Indian manufacturers, Taiwan buyers should implement the following audit and monitoring procedures:

By adhering to these guidelines, Taiwan buyers can effectively qualify Indian suppliers of Acyclovir formulations, ensuring product quality, regulatory compliance, and patient safety.